⏳ Fetching live dividend data...
Home › Calculator › SAGE Dividend Calculator 2026
Sage Therapeutics, Inc. · NASDAQ
Price: $8.68 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in SAGE → $12.78M in 10 years · $239.66/month
Sage Therapeutics, Inc. functions as a biopharmaceutical enterprise, dedicated to the discovery, development, and market introduction of therapeutic agents aimed at central nervous system (CNS) conditions. Its primary medication is ZULRESSO, an intravenous form of brexanolone, prescribed for the treatment of postpartum depression (PPD) in adult patients. The company's advanced pipeline includes zuranolone, a neuroactive steroid, which is presently undergoing Phase III clinical trials for several disorders, such as PPD, major depressive disorders, treatment-resistant depression, generalized anxiety disorders, and bipolar depression. Another investigational compound, SAGE-324, is in Phase II studies for essential tremors, having already completed Phase I trials for epilepsy and Parkinson's disease. Furthermore, SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, has concluded its Phase I clinical assessments for a range of indications including depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. To enhance its global reach and innovative efforts, Sage Therapeutics has established significant collaborations. This comprises a strategic partnership with Shionogi & Co., Ltd. for the advancement and commercialization of zuranolone in Japan, Taiwan, and South Korea. Additionally, the company holds a collaboration and licensing agreement with Biogen MA Inc. for the joint development and marketing of its SAGE-217 and SAGE-324 products. Incorporated in 2010 and based in Cambridge, Massachusetts, the firm was initially known as Sterogen Biopharma, Inc., before officially changing its name to Sage Therapeutics, Inc. in September 2011.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open SAGE position with:
Real after-tax yield depends on where you live and how you hold SAGE.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 23.04% | 20.24% | $2,304 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 19.58% | 16.78% | $1,958 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 18.43% | 15.63% | $1,843 / yr |
| 🇬🇧 UK ISA | 0% | 23.04% | 20.24% | $2,304 / yr |
| 🇬🇧 UK Taxable | 8.75% | 21.02% | 18.22% | $2,102 / yr |
| 🇨🇦 TFSA | 0% | 23.04% | 20.24% | $2,304 / yr |
| 🇨🇦 CA Taxable | 25% | 17.28% | 14.48% | $1,728 / yr |
| 🇦🇺 Super (pension) | 15% | 19.58% | 16.78% | $1,958 / yr |
| 🇦🇺 AU Taxable | 30% | 16.13% | 13.33% | $1,613 / yr |
| 🇩🇪 DE Taxable | 26.375% | 16.96% | 14.16% | $1,696 / yr |
| 🇫🇷 FR Taxable | 30% | 16.13% | 13.33% | $1,613 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
SAGE pays quarterly — 4 times per year. Next ex-div: TBD.
How SAGE compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for SAGE sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| D-Return | 2025-07-31 | 7,962 | — | — | ||
| D-Return | 2025-07-31 | 36,000 | $6.97 | $250.9K | ||
| D-Return | 2025-07-31 | 4,000 | $7.86 | $31.4K | ||
| D-Return | 2025-07-31 | 24,999 | $3.50 | $87.5K | ||
| D-Return | 2025-07-31 | 21,500 | $6.77 | $145.6K | ||
| D-Return | 2025-07-31 | 12,500 | $6.05 | $75.6K | ||
| D-Return | 2025-07-31 | 40,000 | $6.97 | $278.8K | ||
| D-Return | 2025-07-31 | 28,053 | $3.50 | $98.2K | ||
| D-Return | 2025-07-31 | 36,375 | — | — | ||
| D-Return | 2025-07-31 | 21,500 | $6.77 | $145.6K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the SAGE dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Sage Therapeutics, Inc. (SAGE) is currently trading at $8.68, 90% below its 52-week high. The current dividend yield is 23.04% based on an annual payout of $2.00 per share.
Sage Therapeutics, Inc. (SAGE) is a healthcare stock currently trading at $8.68 with a dividend yield of 23.04%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.
⏱️ Takes 30 seconds · No signup · Free forever